TGTX Net Income Per E B T from 2010 to 2024

TGTX Stock  USD 34.61  0.46  1.31%   
TG Therapeutics Net Income Per E B T yearly trend continues to be fairly stable with very little volatility. Net Income Per E B T is likely to outpace its year average in 2024. During the period from 2010 to 2024, TG Therapeutics Net Income Per E B T regression line of annual values had r-squared of  0.09 and arithmetic mean of  1.00. View All Fundamentals
 
Net Income Per E B T  
First Reported
2010-12-31
Previous Quarter
0.9701424
Current Value
1.03
Quarterly Volatility
0.08699771
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check TG Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TG Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 444.1 K, Interest Expense of 13.2 M or Total Revenue of 245.3 M, as well as many indicators such as Price To Sales Ratio of 9.86, Dividend Yield of 4.0E-4 or PTB Ratio of 15.86. TGTX financial statements analysis is a perfect complement when working with TG Therapeutics Valuation or Volatility modules.
  
Check out the analysis of TG Therapeutics Correlation against competitors.
For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.

Latest TG Therapeutics' Net Income Per E B T Growth Pattern

Below is the plot of the Net Income Per E B T of TG Therapeutics over the last few years. It is TG Therapeutics' Net Income Per E B T historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TG Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Income Per E B T10 Years Trend
Slightly volatile
   Net Income Per E B T   
       Timeline  

TGTX Net Income Per E B T Regression Statistics

Arithmetic Mean1.00
Geometric Mean1.00
Coefficient Of Variation8.69
Mean Deviation0.05
Median1.03
Standard Deviation0.09
Sample Variance0.01
Range0.3384
R-Value0.31
Mean Square Error0.01
R-Squared0.09
Significance0.27
Slope0.01
Total Sum of Squares0.11

TGTX Net Income Per E B T History

2023 0.97
2022 1.03
2013 1.04
2012 0.7
2011 0.96
2010 1.02

About TG Therapeutics Financial Statements

TG Therapeutics investors use historical fundamental indicators, such as TG Therapeutics' Net Income Per E B T, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TG Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Income Per E B T 0.97  1.03 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for TGTX Stock Analysis

When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.